Caplin Point Laboratories Receives FDA Form 483 With 10 Observations

An unannounced US FDA inspection of Caplin Steriles’ Gummidipoondi injectable and ophthalmic facility concluded with 10 Form 483 observations. The company characterized them as procedural, with no data-integrity or repeat findings, and will respond within the stipulated timeframe.